Sertolizumab Tedavisine Sekonder Demiyelizan Hastalık Geçiren Bir Vaka
Abstract
Anti-TNFa ajanları çeşitli otoimmün ve inflamtuvar barsak hastalıklarında alternatif tedavi olarak üretilmiştir. Klinik etkinliklerine rağmen anti-TNFa ajanları SSS’inde demyelinizasyon yaptığına dair çeşitli nörolojik yan etkiler yaptığı literatürde belirtilmiştir. Biz bu makalemizde anti-TNFa ajanların beşincisi olan sertolizumaba bağlı demyelinizasyon gelişen bir vakayı inceledik.32 yaşında bayan hastada klinik şikayeti çift ve bulanık görmeydi. Hastanın anti-TNFa ajan kesilip pulse steroid verildikten sonra hastanın şikayetleri geriledi.
Keywords
References
- KAYNAKÇA1) Feldmann M, Steinman L. Design of effective immunotheraphy for human autoimmunity. Nature 2005;435(7042):612-9.2)Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol 2015;27(1):55-623) J. Lin, D. Ziring, S. Desai et al., “TNF𝛼 blockade in human diseases: an overview of efficacy and safety,” Clinical Immunology, vol. 126, no. 1, pp. 13–30, 2008. 4)M. P. Karampetsou, S. N. C. Liossis, and P. P. Sfikakis, “TNF-𝛼 antagonists beyond approved indications: stories of success and prospects for the future,” QJM, vol. 103, no. 12, pp. 917–928, 20105) K. L. Hyrich, A. J. Silman, K. D. Watson, and D. P. M. Symmons, “Anti-tumour necrosis factor 𝛼 therapy in rheumatoid arthritis: an update on safety,” Annals of the Rheumatic Diseases, vol. 63, no. 12, pp. 1538–1543, 2004. 6)A. T. Borchers, N. Leibushor, G. S. Cheema, S. M. Naguwa, and M. E. Gershwin, “Immune mediated adverse effects of biological used in the treatment of rheumatic diseases,” Journal of Autoimmunity, vol. 37, no. 4, pp. 273–288, 2011.7) B. W. Van Oosten, F. Barkhof, L. Truyen et al., “Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2,” Neurology, vol. 47, no. 6, pp. 1531–1534, 1996. 8) The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, “TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study,” Neurology, vol. 53, no. 3, pp. 457–465, 1999. 9)N. Mohan, E. T. Edwards, T. R. Cupps et al., “Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides,” Arthritis & Rheumatism, vol. 44, no. 12, pp. 2862–2869, 2001. 10) H. J. Freeman and B. Flak, “Demyelination-like syndrome in Crohn’s disease after infliximab therapy,” Canadian Journal of Gastroenterology, vol. 19, no. 5, pp. 313–316, 2005.11) M. Tanno, I. Nakamura, S. Kobayashi, K. Kurihara, and K. Ito, “New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients,” Clinical Rheumatology, vol. 25, no. 6, pp. 929–933, 200612) Weir N, Athwal D, Brown D, et al. A new generation of highaffinity humanized pegylated Fab fragment anti-tumor necrosis factor-α antibodies. Therapy 2006;3:535–45.13) Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36.14) Cimzia(R) [package insert]. Smyrna, GA: UCB, Inc; 2016. https://www.cimzia.com/sites/ default/files/docs/Prescribing_Information.pdf. Accessed October 23, 2017. 15)Remicade (R) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2013. https://www. remicade.com/shared/product/remicade/ prescribing-information.pdf. Accessed October 23, 2017. 16) Enbrel (R) [package insert]. Thousand Oaks, CA: Immunex Corporation; 2012. https://www. accessdata.fda.gov/drugsatfda_docs/label/ 2012/103795s5503lbl.pdf. Accessed October 23, 2017. 17)Humira (R) [package insert]. North Chicago, IL: Abbott Laboratories; 2011. https://www. accessdata.fda.gov/drugsatfda_docs/label/2011/ 125057s0276lbl.pdf. Accessed October 23, 2017. 18)Simponi (R) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2011. https://www. accessdata.fda.gov/drugsatfda_docs/label/ 2011/125289s0064lbl.pdf. Accessed October 23, 2017
Details
Primary Language
Turkish
Subjects
Health Care Administration
Journal Section
Case Report
Authors
İlhan Yıldırım
*
0000-0003-0600-7249
Türkiye
Publication Date
December 16, 2019
Submission Date
November 20, 2018
Acceptance Date
November 16, 2019
Published in Issue
Year 2019 Volume: 9 Number: 4